Atlas FDA

VENTANA MMR RxDx Panel, VENTANA ANTI-MLH1 (M1), VENTANA ANTI-MSH6 (SP93), VENTANA ANTI-MSH2 (G219-1129), VENTANA ANTI-PM

FDA premarket approval P200019/S008 · decided 2023-11-08

Approval details

PMA number
P200019
Supplement
S008
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
VENTANA MMR RxDx Panel, VENTANA ANTI-MLH1 (M1), VENTANA ANTI-MSH6 (SP93), VENTANA ANTI-MSH2 (G219-1129), VENTANA ANTI-PM
Generic name
Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay
Applicant
Ventana Medical Systems
Date received
2023-10-26
Decision date
2023-11-08
Days to decision
13 days
Decision code
OK30
Product code
QNH
Advisory committee
Pathology
Expedited review
No
Location
Tucson, AZ
Statement
addition of an alternative supplier for dispenser component parts

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
VENTANA anti-MLH-1(M1) Mouse Monoclonal Primary Antibody, VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary Antibody, VENTANA anti-MSH6 (SP 93) Mouse Monoclonal Primary Antibody, VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody (DEN170030)Ventana Medical Systems2017-10-27